Literature DB >> 19912057

Hydropathic analysis and biological evaluation of stilbene derivatives as colchicine site microtubule inhibitors with anti-leukemic activity.

Ashutosh Tripathi1, David Durrant, Ray M Lee, Riccardo Baruchello, Romeo Romagnoli, Daniele Simoni, Glen E Kellogg.   

Abstract

The crucial role of the microtubule in cell division has identified tubulin as a target for the development of therapeutics for cancer; in particular, tubulin is a target for antineoplastic agents that act by interfering with the dynamic stability of microtubules. A molecular modeling study was carried out to accurately represent the complex structure and the binding mode of a new class of stilbene-based tubulin inhibitors that bind at the alphabeta-tubulin colchicine site. Computational docking along with HINT (Hydropathic INTeractions) score analysis fitted these inhibitors into the colchicine site and revealed detailed structure-activity information useful for inhibitor design. Quantitative analysis of the results was in good agreement with the in vitro antiproliferative activity of these derivatives (ranging from 3 nM to 100 muM) such that calculated and measured free energies of binding correlate with an r(2) of 0.89 (standard error +/- 0.85 kcal mol(-1)). This correlation suggests that the activity of unknown compounds may be predicted.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19912057      PMCID: PMC2782887          DOI: 10.3109/14756360902787055

Source DB:  PubMed          Journal:  J Enzyme Inhib Med Chem        ISSN: 1475-6366            Impact factor:   5.051


  16 in total

Review 1.  Hydrophobicity: is LogP(o/w) more than the sum of its parts?

Authors:  G Eugene Kellogg; D J Abraham
Journal:  Eur J Med Chem       Date:  2000 Jul-Aug       Impact factor: 6.514

Review 2.  Microtubules as a target for anticancer drugs.

Authors:  Mary Ann Jordan; Leslie Wilson
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

3.  Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain.

Authors:  Raimond B G Ravelli; Benoît Gigant; Patrick A Curmi; Isabelle Jourdain; Sylvie Lachkar; André Sobel; Marcel Knossow
Journal:  Nature       Date:  2004-03-11       Impact factor: 49.962

4.  A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach.

Authors:  Tam Luong Nguyen; Connor McGrath; Ann R Hermone; James C Burnett; Daniel W Zaharevitz; Billy W Day; Peter Wipf; Ernest Hamel; Rick Gussio
Journal:  J Med Chem       Date:  2005-09-22       Impact factor: 7.446

5.  Structure of the alpha beta tubulin dimer by electron crystallography.

Authors:  E Nogales; S G Wolf; K H Downing
Journal:  Nature       Date:  1998-01-08       Impact factor: 49.962

6.  Development and validation of a genetic algorithm for flexible docking.

Authors:  G Jones; P Willett; R C Glen; A R Leach; R Taylor
Journal:  J Mol Biol       Date:  1997-04-04       Impact factor: 5.469

7.  Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4'-trimethoxystilbene.

Authors:  Mirella Belleri; Domenico Ribatti; Stefania Nicoli; Franco Cotelli; Luca Forti; Vanio Vannini; Lucia Anna Stivala; Marco Presta
Journal:  Mol Pharmacol       Date:  2005-02-09       Impact factor: 4.436

8.  Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents.

Authors:  Marinella Roberti; Daniela Pizzirani; Daniele Simoni; Riccardo Rondanin; Riccardo Baruchello; Caterina Bonora; Filippo Buscemi; Stefania Grimaudo; Manlio Tolomeo
Journal:  J Med Chem       Date:  2003-07-31       Impact factor: 7.446

9.  Development of water soluble derivatives of cis-3, 4', 5-trimethoxy-3'-aminostilbene for optimization and use in cancer therapy.

Authors:  David E Durrant; Joanna Richards; Ashutosh Tripathi; Glen E Kellogg; Paolo Marchetti; Marco Eleopra; Giuseppina Grisolia; Daniele Simoni; Ray M Lee
Journal:  Invest New Drugs       Date:  2008-05-31       Impact factor: 3.850

Review 10.  Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle.

Authors:  A Jordan; J A Hadfield; N J Lawrence; A T McGown
Journal:  Med Res Rev       Date:  1998-07       Impact factor: 12.944

View more
  4 in total

1.  Novel piperidine derivatives as colchicine binding site inhibitors induce apoptosis and inhibit epithelial-mesenchymal transition against prostate cancer PC3 cells.

Authors:  Dong-Jun Fu; Si-Meng Liu; Jia-Jia Yang; Jun Li
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

2.  Discovery of new quinolines as potent colchicine binding site inhibitors: design, synthesis, docking studies, and anti-proliferative evaluation.

Authors:  Mohamed Hagras; Moshira A El Deeb; Heba S A Elzahabi; Eslam B Elkaeed; Ahmed B M Mehany; Ibrahim H Eissa
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

3.  Design, eco-friendly synthesis, molecular modeling and anticancer evaluation of thiazol-5(4H)-ones as potential tubulin polymerization inhibitors targeting the colchicine binding site.

Authors:  Abeer M El-Naggar; Ibrahim H Eissa; Amany Belal; Amira A El-Sayed
Journal:  RSC Adv       Date:  2020-01-15       Impact factor: 4.036

4.  Antiproliferative benzothiazoles incorporating a trimethoxyphenyl scaffold as novel colchicine site tubulin polymerisation inhibitors.

Authors:  Dong-Jun Fu; Si-Meng Liu; Fu-Hao Li; Jia-Jia Yang; Jun Li
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.